Baird Medical Investment Holdings Limited (BDMDW) 주식 분석

회사 개요

Baird Medical Investment Holdings Limited (BDMDW) is a specialized entity engaged in the research, development, manufacturing, and sales of microwave ablation apparatus, needles, and other medical devices within the People's Republic of China. Although the specific sector and industry classifications are not disclosed in current public data, the company operates within the broader medical device manufacturing landscape, focusing on thermal ablation technologies used for medical treatments. The firm employs a workforce of 143 individuals to support its operations across the Chinese market. However, the company's market capitalization and annual revenue figures are not currently available in the provided valuation data, which limits the ability to quantify its precise market position relative to peers. Consequently, the absence of market cap data suggests that the company may be in a developmental stage or faces significant volatility that prevents standard market valuation metrics from being established or reported.

재무 건전성

Baird Medical Investment Holdings Limited reported total revenue of $31.86 million over the trailing twelve months, yet it recorded a net income loss of $3,170,793 during the same period. The substantial gap between positive revenue of $31.86 million and negative net income indicates a severe cost structure issue where operating expenses and other costs significantly exceeded gross profits, resulting in an operating margin of -131.3%. Despite the net loss, the company generated an EBITDA of $919,415, suggesting that core operational cash generation before interest and taxes remains positive despite the accounting losses. Furthermore, the company maintains a free cash flow of $2.52 million and holds $2.50 million in cash reserves, providing a degree of financial flexibility to fund operations or invest in R&D without immediate external financing. However, the company carries a total debt load of $22.56 million, resulting in a debt-to-equity ratio of 63.33, which characterizes the balance sheet as highly leveraged rather than conservative. The current ratio stands at 1.71, indicating that the company possesses sufficient current assets to cover its short-term liabilities with a margin of safety above one. Additionally, the Return on Equity is -8.0% and the Return on Assets is -0.2%, revealing that management has not yet generated positive returns on the capital invested by shareholders or utilized in assets to generate profit.

밸류에이션 평가

The trailing twelve-month P/E ratio and forward P/E ratio are both listed as not applicable (N/A) due to the company's negative earnings, which implies that traditional earnings-based valuation models cannot be applied to assess future earnings trajectories. Instead, the price-to-book ratio is recorded at 0.07, indicating that the market is valuing the company at a fraction of its book value, suggesting a significant discount or potential distress valuation rather than a premium over book value. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are also not available for analysis, leaving investors without standard multiples to gauge relative value against industry peers. The stock's 52-week trading range shows a high of $0.10 and a low of $0.10, meaning the current price is trading exactly at the midpoint of this narrow range with no intraday variation recorded in the data. The beta value is -1.16, a negative figure that indicates the stock's price volatility moves inversely to the broader market, exhibiting an unusual correlation pattern that does not align with standard equity behavior.

Growth & Income

Revenue growth on a year-over-year basis has declined by 39.4%, while earnings growth is not available for comparison due to the negative net income position. The negative revenue growth suggests a contraction in sales volume or pricing power, and without positive earnings growth to offset this, the company's financial performance is deteriorating. As the company does not pay dividends, the dividend yield and payout ratio are not applicable, meaning the firm does not distribute cash to shareholders but instead retains its limited cash flow for internal use. The overall growth and income profile for Baird Medical Investment Holdings Limited is characterized by significant revenue contraction, a lack of dividend income, and a valuation environment where traditional metrics are unavailable due to negative earnings and high leverage.